Unmet Needs in BRAF+ NSCLC

preview_player
Показать описание
Current challenges surrounding the management of patients with non–small cell lung cancer who present with BRAF mutations.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Unmet Needs in 0:01:58

Unmet Needs in BRAF+ NSCLC

NSCLC: Take-Home Messages 0:03:59

NSCLC: Take-Home Messages and Unmet Needs

Dr. Bauman on 0:01:51

Dr. Bauman on Treatments for Patients With BRAF-Mutant NSCLC

Changing Treatment Paradigm 0:09:16

Changing Treatment Paradigm for BRAF-Mutant NSCLC

Dr Nandini Menon 0:22:16

Dr Nandini Menon | Meeting the unmet need in NSCLC patients with MET exon 14 alterations

Dr. Ullas Batra 0:12:19

Dr. Ullas Batra - Unlocking the unMET Need in met Ex14 M NSCLC

NSCLC Stage III 0:03:46

NSCLC Stage III Unmet Needs and Practical Advice

Targeting BRAF in 0:03:10

Targeting BRAF in NSCLC

Patient Selection in 0:05:55

Patient Selection in BRAF-Mutant NSCLC

Progression of BRAF 0:04:58

Progression of BRAF V600E+ Metastatic NSCLC

Dr. Camidge Discusses 0:01:00

Dr. Camidge Discusses Unmet Needs in ALK+ Lung Cancer

Ulixertinib in tumors 0:02:45

Ulixertinib in tumors with BRAF fusions, non-V600E or non-V600K BRAF mutations

Advice for BRAF 0:00:29

Advice for BRAF Patients: Debbie

Taking Aim With 0:48:40

Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC to Address Unmet Needs

Answers to Key 1:00:29

Answers to Key Questions About Antibody–Drug Conjugates in NSCLC

BRAF - Dr 0:17:37

BRAF - Dr Ullas Batra - Selection Of 1st Line Targeted Therapy For BRAF Mutated NSCLC

Dr Niti Raizada 0:15:07

Dr Niti Raizada | Targeted Treatment for BRAFV600E & MET exon14 mutated NSCLC

Addressing Key Targets 0:58:27

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted Therapies

Excluding Inappropriate Treatment 0:04:04

Excluding Inappropriate Treatment Approaches in NSCLC

Dabrafenib Plus Trametinib 0:03:18

Dabrafenib Plus Trametinib for the Treatment of mNSCLC

Off-Label Crizotinib for 0:03:24

Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

Treatment of Locally 0:11:22

Treatment of Locally Advanced NSCLC

Selective, Potent, Different: 0:50:46

Selective, Potent, Different: Next-Generation ROS1 and TRK Inhibition in NSCLC and Other Tumors

VISION: tepotinib in 0:06:13

VISION: tepotinib in MET exon 14 skipping NSCLC